SAB BIOTHERAPEUTICS INC Stock Price, News & Analysis

SAB BIO (Nasdaq: SABS) initiated its registrational Phase 2b SAFEGUARD trial of lead candidate SAB-142 in new-onset Stage 3 T1D, activated multiple sites in the US, Australia and New Zealand, and is on-track to dose the first patient by year-end 2025. The company reported a strong cash position of $161.5 million at Sept 30, 2025 (vs. $20.8 million at Dec 31, 2024) and said its runway extends through 2028. Phase 1 data presented at EASD and ISPAD showed a favorable safety profile, no serum sickness or anti-drug antibodies at the target dose, and sustained immunomodulation. Financials: Q3 R&D $9.0M, other income $58.1M, and Q3 net income $45.4M. Company expects SAFEGUARD data in 2H 2027 and to present additional Phase 1 redosing data by year-end 2025.

SAb Biotherapeutics (Nasdaq: SABS) will present clinical and translational data for its lead program SAB-142 at the 51st ISPAD Annual Conference in Montréal, Nov 5–8, 2025.

Six presentations (four oral, two posters) describe Phase 1 results showing a multi-specific mechanism of action with sustained immunomodulation, a favorable safety profile at target dose without serum sickness or anti-drug antibodies, and a novel pharmacokinetic assay for measuring SAB-142.

The presentations cover specimen quality methods, binding specificity profiling, immunomodulation without sustained lymphodepletion, mechanism of action, PK assay details, and safety findings, led by SAB BIO scientific and clinical leaders.

SAb Biotherapeutics (Nasdaq: SABS) announced that members of management will participate in three investor conferences in November–December 2025: a UBS Global Healthcare Conference fireside chat on Nov 10, 2025 at 2:45 p.m. ET in West Palm Beach, a Guggenheim Healthcare Innovation Conference fireside chat on Nov 12, 2025 at 10:00 a.m. ET in Boston, and an Evercore Healthcare Conference fireside chat on Dec 2, 2025 at 3:50 p.m. ET in Coral Gables.

Live webcasts and archived recordings will be available on the company Investor Relations Events page at www.sab.bio.

SAB Biotherapeutics (NASDAQ: SABS) presented multiple studies at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), highlighting data for their novel SAB-142 treatment for type 1 diabetes (T1D).

The presentations featured results from their Phase 1 clinical study of SAB-142, a fully human anti-thymocyte immunoglobulin (ATG), which demonstrated sustained immunomodulation without causing prolonged lymphodepletion. The company also shared data about SAB-142's pharmacokinetic profile and discussed the INNODIA-sponsored MELD-ATG study, which validated the disease-modifying potential of ATG therapy in T1D patients.

SAB BIO is currently initiating its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, collaborating with INNODIA and leading European T1D centers.

SAB Biotherapeutics (Nasdaq: SABS) announced its participation at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, from September 15-19, 2025. The company will deliver five presentations focused on SAB-142, their novel immunotherapy treatment for type 1 diabetes.

The presentations include an INNODIA-hosted symposium and four oral presentations covering various aspects of SAB-142, including its immunomodulation properties, mechanism of action, pharmacokinetic assays, and specimen quality analysis for clinical trials. Key speakers include Dr. Alexandra Kropotova, EVP and Chief Medical Officer, Dr. Christoph Bausch, EVP and Chief Operating Officer, and Dr. Eric Sandhurst, Director of Program Management.

SAB BIO (Nasdaq: SABS) has announced significant developments in Q2 2025, highlighted by a $175 million oversubscribed private placement that included strategic investor Sanofi. The financing extends the company's operational runway until mid-2028 and will fully fund their pivotal Phase 2b SAFEGUARD study for SAB-142, their lead candidate for delaying type 1 diabetes progression.

The company achieved FDA alignment on the SAFEGUARD study design, scheduled to begin in Q3 2025. The private placement included issuing 1 million shares of Series B preferred stock at $1.75 per share conversion price, plus warrants for potential additional proceeds of $284 million.

Financial results showed cash position of $5.7 million as of June 30, 2025, with Q2 R&D expenses at $7.0 million and a net loss of $10.1 million.

SAB BIO (Nasdaq: SABS) has secured a significant $175 million private placement with participation from strategic investor Sanofi and several prominent institutional investors. The oversubscribed financing includes the issuance of 1,000,000 shares of Series B nonvoting convertible preferred stock at a conversion price of $1.75 per share.

The company will also issue warrants that could provide up to an additional $284 million in gross proceeds if exercised in full. The proceeds will fund the pivotal Phase 2b SAFEGUARD study of SAB-142 for delaying progression of autoimmune Type 1 Diabetes (T1D) in newly diagnosed patients, extending the company's cash runway into mid-2028.

SAB BIO (NASDAQ: SABS) has reported its Q1 2025 financial results and company updates. The clinical-stage biopharmaceutical company completed patient dosing in the last cohort of the Phase 1 clinical study of SAB-142, their novel immunotherapy for delaying type 1 diabetes progression. The company reported cash and equivalents of $12.9 million, down from $20.8 million in December 2024.

Financial highlights include R&D expenses of $7.7 million (down from $8.1 million YoY), reduced G&A expenses of $3.1 million (down from $4.2 million YoY), and other income of $5.6 million. The company reported a net loss of $5.2 million. SAB BIO also achieved a significant milestone by obtaining a Qualified Person declaration for their in-house CMC manufacturing process, enabling them to meet European manufacturing standards for upcoming EU clinical trials.

SAB BIO (SABS) announced its Q4 and full-year 2024 financial results, highlighting positive topline data from Phase 1 trials of SAB-142, their human anti-thymocyte immunoglobulin therapy for Type 1 Diabetes. The study met primary objectives for safety and pharmacodynamic activity, paving the way for Phase 2b trials expected mid-2025.

Financial highlights for FY2024 include:

• Cash position of $20.8M (down from $56.6M in 2023)
• R&D expenses increased to $30.3M (from $16.5M in 2023)
• G&A expenses decreased to $14.0M (from $23.8M in 2023)
• Net loss improved to $34.1M (from $42.2M in 2023)
• Other net income of $8.8M (compared to $4.1M expense in 2023)